Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: Results from the MERIT trial

HIV Clinical Trials

Volumn 12, Issue 1, 2011, Pages 24-36

  MacInnes, A ^a   Lazzarin, A ^b   Di Perri, G ^c   Sierra Madero, J G ^d   Aberg, J ^e   Heera, J ^f   Rajicic, N ^a   Goodrich, J ^g   Mayer, H ^h   Valdez, H ^a  

^a PFIZER INC   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^g VIIV HEALTHCARE   (United States)

^h EMD Serono   (United States)

Author keywords

cholesterol; HIV infection; lipid profiles; maraviroc; triglycerides

Indexed keywords

CHOLESTEROL; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG APPROVAL; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CYCLOHEXANES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPID METABOLISM; MALE; RECEPTORS, CCR5; TRIAZOLES; TRIGLYCERIDES;

EID: 79952571498     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1201-24     Document Type: Article

References (42)

1. Buchacz K, Rangel M, Blacher R, et al. Changes in the clinical epidemiology of HIV infection in the United States. Implications for the clinician. Curr Infect Dis Rep. 2009;11:75-83.
2. Palella FJJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. (Pubitemid 44306484)
3. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "mortalite 2000 and 2005" surveys (ANRS EN19 and mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
4. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387-1396.
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
6. DAD Study Group, Friis-Møller N, Sabin CA, et al. Com-bination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
7. Ross R. Atherosclerosis\an inflammatory disease. N Engl J Med. 1999;340:115-126.
8. Libby P. Molecular bases of the acute coronary syn-drome. Circulation. 1995;91:2844-2850.
9. Wilcox JN, Nelken NA, Coughlin SR, et al. Local expres-sion of inflammatory cytokines in human atheroscle-rotic plaques. J Atheroscler Thromb. 1994;1(Suppl1): S10-S13.
10. Pattison JM, Nelson PJ, Huie P, et al. RANTES chemokines expression in transplant-associated accelerated athero-sclerosis. J Heart Lung Transplant. 1996;15:1194-1199. (Pubitemid 26428394)
11. Makino Y, Cook DN, Smithies O, et al. Impaired T cell function in RANTES-deficient mice. Clin Immunol. 2002;102:302-309. (Pubitemid 34259264)
12. Bursill CA, Choudhury RP, Ali Z, et al. Broad-spectrum CC-chemokine blockade by gene transfer inhibits mac-rophage recruitment and atherosclerotic plaque forma-tion in apolipoprotein E\knockout mice. Circulation. 2004;110:2460-2466. (Pubitemid 39407354)
13. Braunersreuther V, Zernecke A, Arnaud C, et al. CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2007;27:373-379. (Pubitemid 46143054)
14. van Wanrooij EJA, Happe H, Hauer AD, et al. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2642-2647. (Pubitemid 43732291)
15. Veillard NR, Kwak B, Pelli G, et al. Antagonism of RAN-TES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004;94:253-261. (Pubitemid 38197459)
16. Potteaux S, Combadiere C, Esposito B, et al. Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:1858-1863. (Pubitemid 44305341)
17. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996:1240-1243. (Pubitemid 26375409)
18. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med. 1997:882-890. (Pubitemid 27490625)
19. Afzal AR, Kiechl S, Daryani YP, et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the bruneck population. Stroke. 2008;39:1972-1978.
20. Balistreri CR, Candore G, Caruso M, et al. Role of poly-morphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for lon-gevity Haematologica. 2008;93:637-638. (Pubitemid 351536399)
21. Gonzalez P, Alvarez R, Batalla A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immunity. 2001;2:191-195. (Pubitemid 33676982)
22. Hyde CL, MacInnes A, Sanders FA, et al. Genetic asso-ciation of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010;3: 162-168.
23. Petrkova J, Cermakova Z, Lukl J, et al. CC chemokine receptor 5 (CCR5) deletion polymorphism does not pro-tect Czech males against early myocardial infarction. J Intern Med. 2005;257:564-566. (Pubitemid 40776518)
24. Wilkin T, Ribaudo H, Gulick R. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials. In: Program and abstracts from the 15th Conference on Retroviruses and Opportunistic Infections; 2008. Abstract 800.
25. Funderburg N, Kalinowska M, Eason J, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and their association with CD4 cell rises in HIV-infected patients. PLoS One. 2010;5:e13188.
26. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine/lamivu-dine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1. J Infect Dis. 2010;201:803-813.
27. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evalua-tion, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-3421.
28. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
29. Randell P, Jackson A, Taylor J, et al. The impact of mara-viroc on insulin sensitivity, lipids and adipokines after 2 weeks in HIV-negative male volunteers. Antivir Ther. 2009;14(Suppl 2):A40. Abstract P-18.
30. Triant VA, Lee H, Hadigan C, et al. Increased acute myo-cardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus dis-ease. J Clin Endocrinol Metab. 2007;92:2506-2512. (Pubitemid 47037350)
31. Hsue PY, Lo JC, Franklin A, et al. Progression of ath-erosclerosis as assessed by carotid intima-media thick-ness in patients with HIV infection. Circulation. 2004;109: 1603-1608. (Pubitemid 38451715)
32. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replica-tion, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059-1067.
33. Hsue P, Hunt P, Schnell A, et al. Rapid progression of ath-erosclerosis at the carotid bifurcation is linked to inflam-mation in HIV-infected patients. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, CA.
34. DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
35. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35:e111-e112.
36. Kiser JJ, Gerber JG, Predhomme JA, et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47:570-578. (Pubitemid 351442013)
37. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immu-nodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543. (Pubitemid 36578959)
38. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126-133. (Pubitemid 351263476)
39. Hsue P, Hunt P, Schnell A, et al. Inflammation is associ-ated with endothelial dysfunction among individuals with treated and suppressed HIV infection. In: Program and abstracts from the 17th Conference on Retroviruses and Opportunistic Infections; 2010. Abstract 708.
40. Wilkin T, Lalama C, Tenorio A, et al. Maraviroc (MVC) intensification for suboptimal CD4+ response despite sustained virologic suppression: ACTG 5256. In: Program and abstracts from the 17th Conference on Retroviruses and Opportunistic Infections; 2010. Abstract 285.
41. Gutierrez C, Diaz L, Hernandez-Novoa B, et al. Effect of intensification with a CCR5 antagonist on the decay of the HIV-1 latent reservoir and residual viremia. Paper pre-sented at: 17th Conference on Retroviruses and Opportu-nistic Infections; 2010; San Francisco, CA.
42. Sauzullo I, Lichtner M, Mengoni F, et al. Effect in vitro of CCR5 antagonists on innate immune system: maraviroc inhibits the migration of neutrophils, macrophages, and DC In: Program and abstracts from the 17th Confer-ence on Retroviruses and Opportunistic Infections; 2010. Abstract 512.